Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited ( (AU:MSB) ) just unveiled an update.
Mesoblast used its R&D Day presentation to outline expectations for future sales, revenue, product efficacy, intellectual property strength, regulatory timelines, and manufacturing scalability tied to its adult stem cell technologies. The company also highlighted its reliance on partners, capital requirements, and regulatory and clinical trial risks, underscoring that actual performance may differ materially from current projections and that investors should not place undue reliance on forward-looking statements.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited, listed on the ASX and Nasdaq, is a biotechnology company focused on developing and commercializing adult stem cell technologies. Its core activities center on advancing cell-based therapies, supported by intellectual property, scalable manufacturing processes, and a strategy that depends on regulatory approvals and collaborations.
Average Trading Volume: 4,173,671
Technical Sentiment Signal: Hold
Current Market Cap: A$2.75B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.